Literature DB >> 25916046

Association between chronic use of proton pump inhibitors and small- intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests.

Yasuhiro Fujiwara, Toshio Watanabe, Motoko Muraki, Hirokazu Yamagami, Tetsuya Tanigawa, Masatsugu Shiba, Kazunari Tominaga, Tetsuo Arakawa.   

Abstract

BACKGROUND/AIMS: Several adverse events have been reported in patients who are chronic users of proton pump inhibitors (PPIs); however, the association between PPI use and small-intestinal bacterial overgrowth (SIBO) is controversial. We examined the prevalence of SIBO, as assessed by the lactulose hydrogen breath test (LHBT), based on the use of gastric acid-suppressive drugs in Japanese patients. METH- ODOLOGY: Ninety-four patients who were examined by the LHBT were assessed retrospectively. We used several criteria to define a positive LHBT result. Nine patients received probiotics containing Lactobacillus casei.
RESULTS: Fifty patients were PPI users, 14 were histamine-2 receptor antagonist (H2RA) users, and were 30 non-PPI and non-H2RA users (controls). There were no significant differences in prevalence of LHBT-positive cases among the three groups. Multiple-adjusted regression showed no significant association between PPI use and being LHBT-positive. Prevalence of postprandial fullness in PPI users was high (46%), but such symptoms were not related to LHBT results. Four (44%) of 9 cases became LHBT-negative and the maximal peak of H2 production decreased significantly after probiotic treatment.
CONCLUSIONS: PPI treatment is not associated with SIBO in Japanese patients. Mechanisms apart from SIBO could cause the high prevalence of postprandial fullness in PPI users.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25916046

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Influence of proton pump inhibitors on microbiota in chronic liver disease patients.

Authors:  Kenta Yamamoto; Masatoshi Ishigami; Takashi Honda; Tomoaki Takeyama; Takanori Ito; Yoji Ishizu; Teiji Kuzuya; Kazuhiko Hayashi; Hidemi Goto; Yoshiki Hirooka
Journal:  Hepatol Int       Date:  2019-02-08       Impact factor: 6.047

Review 2.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

3.  Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis.

Authors:  Binrui Chen; John Jae-Woo Kim; Yawen Zhang; Lijun Du; Ning Dai
Journal:  J Gastroenterol       Date:  2018-05-14       Impact factor: 7.527

Review 4.  Enhancing High Value Care in Gastroenterology Practice.

Authors:  Michael Camilleri; David A Katzka
Journal:  Clin Gastroenterol Hepatol       Date:  2016-05-20       Impact factor: 11.382

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.